All News

The combination of (Cyramza) ramucirumab with docetaxel was today approved by the FDA for the treatment of advanced non-small cell lung cancer and in those who have been treated with platinum-based therapy.

Iowa quietly and successfully implemented a unique form of Medicaid expansion and revamped mental health services in 2014. But will budget problems unravel all the good news next year?

Actor and singer Charles Esten, whose daughter was diagnosed with leukemia when she was 2-and-a-half, shares the challenging and painful experiences of battling the disease.

Stick to pathways or use them as guidance? A physician explores.

The rule being published tomorrow not only grants same-sex spouses the right to act as medical decision-makers, but it also requires Medicare and Medicaid providers to inform patients of these rights.

A new report has validated concerns that CMS readmission penalty models do not factor in socioeconomic and race factors and therefore unfairly penalize hospitals caring for low-income, uninsured, and vulnerable populations.

A majority of breast cancer patients in the US are receiving longer radiation therapy than is necessary and compared with their counterparts in other countries, according to a new study published in JAMA.

The Aetna Foundation announced the Healthier World Innovation Challenge, a $4.5 million initiative designed to steer digital health innovation to improve chronic health outcomes in underserved communities.

As Medicaid enrollment grows under the program's expansion, there are not enough providers to serve the increased amounts of enrollees, according to a new report from the Office of the Inspector General that measured the availability of specific providers in Medicaid managed care networks.

The study published in Health Affairs recommends standardization of benefit plans across states for children, especially those related to developmental abilities.

Blue Shield of California seeks regulatory approval to buy Care1st, which would give the larger insurer a rapidly growing Medicaid plan. Commercial carriers are expected to eye Medicaid plans as a source of growth, especially in states that have approved expansion.

Highly-paid doctors make more money ordering multiple procedures for individual patients than they earn seeing multiple patients, suggesting payment reform under the Affordable Care Act has yet to be realized.

Health centers across the country will receive $36.3 million in Affordable Care Act funding to invest in ongoing quality improvement activities, HHS announced on Tuesday.

The federal government may have made strides to improve the health insurance exchanges since last year's open enrollment, but a majority of Americans view shopping for health insurance as just as bad as or worse than doing their taxes.

A new stroke care delivery model developed by researchers at the Stanford Clinical Excellence Research Center could lower US healthcare costs by as much as $1.6 billion per year, according to a study published in Stroke.

Overuse of scans, transfusions, and the length of time on anticoagulants received attention in the latest round of recommendations presented Monday, as part of the initiative across medicine to improve patient care with an eye toward controlling costs.

Results from a large phase 3 prospective randomized open-label trial, comparing imatinib 400 mg with dasatinib 100 mg daily, were presented by Stephen O'Brien, MD, professor of hematology, Newcastle University Medical School, Newcastle upon Tyne, England.

On Monday, the third day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9, in San Francisco, Jeffrey H. Lipton, MD, PhD, chief, presented results from the EPIC trial, evaluating ponatinib in patients with newly diagnosed chronic phase chronic myelogenous leukemia.

There are many ways patients with chronic myelogenous leukemia can ensure they are active participants in their own treatment, according to Giora Sharf, co-founder of the CML Advocates Network.

Although guidelines from the National Comprehensive Cancer Network and recommendations from the European LeukemiaNet do not identify a failure time point for major molecular response in patients with chronic myelogenous leukemia, a study at the 56th Annual Meeting of the American Society of Hematology was able to pinpoint when treatment is not working.

Republicans in the US Congress plan to renew their attacks on President Barack Obama and his signature healthcare plan on Tuesday when they grill a consultant who said "the stupidity of the American voter" helped ensure the law's passage.

One criticism of the Affordable Care Act is that it imposes a costly, one-size-fits-all standard, drastically increasing premiums by requiring everyone to buy health insurance that covers the same mandated benefits. This is not so.

The updated federal health information technology strategic plan is an attempt to collect, share, and use interoperable health information to improve care; enhance individual, community, and public health; and advance research.

A poster session on the second day of the 56th annual meeting of the American Society of Hematology, held December 6-9, San Francisco, was dedicated to trials evaluating therapeutic options in chronic myelogenous leukemia. Data presented included safety, efficacy, managing comorbidities, and biological differences that drive response to therapy.

Perceptions of chronic myelogenous leukemia (CML) and how to live with it are very different for patients and physicians, and a strong dialogue is needed to overcome the disparity, according to Jan Geissler, co-founder of the CML Advocates Network.

Although nilotinib as a first-line therapy for chronic myelogenous leukemia is a more effective treatment than imatinib, nilotinib's side effects are too much for patients.

On the second day at the Annual Meeting of the American Society of Hematology 2014, Francois-Xavier Mahon, MD, PhD, Bordeaux Hospital, INSERM 1035, Bordeaux, France, shared the results from the European LeukemiaNet Stop TKI (EURO-SKI) study; the trial used tyrosine kinase inhibitors (TKIs) in CML to define prognostic markers to increase the rate of patients in durable deep molecular response after stopping TKI.

Representatives from industry and the FDA share perspectives on the state of regulation for therapeutics and diagnostics at the 56th annual meeting of the American Society of Hematology, being held in San Francisco.

One of the reoccurring themes at the 56th Annual Meeting of the American Society of Hematology was the importance of proper monitoring, said Greg Stephens, executive director of the National CML Society.

The hypothetical risk of illness is enough of a motivating factor for people to take action, according to a study published in the Journal of Health and Social Behavior.